DDInter513 DDInter1435
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Dexamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Dexamethasone {u} (Compound) resembles {v} (Compound) Triamcinolone
Dexamethasone {u} (Compound) treats {v} (Disease) psoriatic arthritis
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dexamethasone {u} (Compound) upregulates {v} (Gene) PCYOX1L
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Dexamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Dexamethasone {u} (Compound) downregulates {v} (Gene) DNAJB6
Dexamethasone {u} (Compound) causes {v} (Side Effect) Vitreous opacities
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Dexamethasone (Compound) resembles Triamcinolone (Compound)
Dexamethasone (Compound) treats psoriatic arthritis (Disease)
Dexamethasone (Compound) binds CYP3A7-CYP3A51P (Gene)
Dexamethasone (Compound) upregulates PCYOX1L (Gene)
Dexamethasone (Compound) palliates kidney cancer (Disease)
Dexamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Dexamethasone (Compound) downregulates DNAJB6 (Gene)
Dexamethasone (Compound) causes Vitreous opacities (Side Effect)
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate